Header Logo

Connection

PAVAN REDDY to Transplantation, Homologous

Back to Details
This is a "connection" page, showing publications PAVAN REDDY has written about Transplantation, Homologous.
PAVAN REDDY
Connection Strength
4.167
Transplantation, Homologous
  1. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res. 2007 Oct; 150(4):197-214.
    View in: PubMed
    Score: 0.239
  2. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. Blood. 2024 01 04; 143(1):21-31.
    View in: PubMed
    Score: 0.187
  3. Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Adv. 2021 12 14; 5(23):5047-5056.
    View in: PubMed
    Score: 0.163
  4. RNA-seq of human T cells after hematopoietic stem cell transplantation identifies Linc00402 as a regulator of T cell alloimmunity. Sci Transl Med. 2021 03 17; 13(585).
    View in: PubMed
    Score: 0.154
  5. Targeting Signal 3 Extracellularly and Intracellularly in Graft-Versus-Host Disease. Front Immunol. 2020; 11:722.
    View in: PubMed
    Score: 0.145
  6. Computational analysis of continuous body temperature provides early discrimination of graft-versus-host disease in mice. Blood Adv. 2019 12 10; 3(23):3977-3981.
    View in: PubMed
    Score: 0.141
  7. Host NLRP6 exacerbates graft-versus-host disease independent of gut microbial composition. Nat Microbiol. 2019 05; 4(5):800-812.
    View in: PubMed
    Score: 0.134
  8. Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation. J Immunol. 2018 12 01; 201(11):3443-3455.
    View in: PubMed
    Score: 0.131
  9. Murine Models of Steroid Refractory Graft-versus-Host Disease. Sci Rep. 2018 08 20; 8(1):12475.
    View in: PubMed
    Score: 0.129
  10. Non-Coding RNA Mediated Regulation of Allogeneic T Cell Responses After Hematopoietic Transplantation. Front Immunol. 2018; 9:1110.
    View in: PubMed
    Score: 0.128
  11. STAT3 Expression in Host Myeloid Cells Controls Graft-versus-Host Disease Severity. Biol Blood Marrow Transplant. 2017 Oct; 23(10):1622-1630.
    View in: PubMed
    Score: 0.120
  12. Advances in understanding the pathogenesis of graft-versus-host disease. Br J Haematol. 2016 Apr; 173(2):190-205.
    View in: PubMed
    Score: 0.109
  13. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol. 2016 05; 17(5):505-513.
    View in: PubMed
    Score: 0.109
  14. BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood. 2015 Apr 23; 125(17):2724-8.
    View in: PubMed
    Score: 0.102
  15. Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans. Blood. 2015 Jan 29; 125(5):815-9.
    View in: PubMed
    Score: 0.100
  16. Current and emerging strategies for the prevention of graft-versus-host disease. Nat Rev Clin Oncol. 2014 Sep; 11(9):536-47.
    View in: PubMed
    Score: 0.097
  17. Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1407-17.
    View in: PubMed
    Score: 0.096
  18. Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1426-34.
    View in: PubMed
    Score: 0.096
  19. Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. Blood. 2014 May 29; 123(22):3512-23.
    View in: PubMed
    Score: 0.095
  20. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014 Jan; 15(1):87-95.
    View in: PubMed
    Score: 0.093
  21. Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation. Blood. 2013 May 16; 121(20):4231-41.
    View in: PubMed
    Score: 0.089
  22. Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease. J Leukoc Biol. 2012 Apr; 91(4):667-75.
    View in: PubMed
    Score: 0.082
  23. GVHD prevention: an ounce is better than a pound. Biol Blood Marrow Transplant. 2012 Jan; 18(1 Suppl):S17-26.
    View in: PubMed
    Score: 0.082
  24. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A. 2012 Jan 10; 109(2):564-9.
    View in: PubMed
    Score: 0.081
  25. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res. 2011 Jan 01; 17(1):77-88.
    View in: PubMed
    Score: 0.075
  26. Immunization with host-type CD8{alpha}+ dendritic cells reduces experimental acute GVHD in an IL-10-dependent manner. Blood. 2010 Jan 21; 115(3):724-35.
    View in: PubMed
    Score: 0.070
  27. Emerging drugs for acute graft-versus-host disease. Expert Opin Emerg Drugs. 2009 Jun; 14(2):219-32.
    View in: PubMed
    Score: 0.068
  28. Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease. Exp Hematol. 2008 Aug; 36(8):988-96.
    View in: PubMed
    Score: 0.063
  29. Biological advances in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation. 2008 Feb 15; 85(3):303-8.
    View in: PubMed
    Score: 0.062
  30. A novel role for the semaphorin Sema4D in the induction of allo-responses. Biol Blood Marrow Transplant. 2007 Nov; 13(11):1294-1303.
    View in: PubMed
    Score: 0.061
  31. Lymphopenia-induced proliferation of donor T cells reduces their capacity for causing acute graft-versus-host disease. Exp Hematol. 2007 Feb; 35(2):274-86.
    View in: PubMed
    Score: 0.058
  32. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med. 2005 Nov; 11(11):1244-9.
    View in: PubMed
    Score: 0.053
  33. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation. Blood. 2004 Nov 15; 104(10):3393-9.
    View in: PubMed
    Score: 0.049
  34. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A. 2004 Mar 16; 101(11):3921-6.
    View in: PubMed
    Score: 0.047
  35. Pathophysiology of acute graft-versus-host disease. Hematol Oncol. 2003 Dec; 21(4):149-61.
    View in: PubMed
    Score: 0.047
  36. Allogeneic T cells cause acute renal injury after hematopoietic cell transplantation. Blood Adv. 2023 11 28; 7(22):6936-6948.
    View in: PubMed
    Score: 0.047
  37. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood. 2003 Apr 01; 101(7):2877-85.
    View in: PubMed
    Score: 0.043
  38. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation. Blood. 2002 Nov 01; 100(9):3429-31.
    View in: PubMed
    Score: 0.043
  39. Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults. Biol Blood Marrow Transplant. 2020 05; 26(5):e101-e112.
    View in: PubMed
    Score: 0.036
  40. Survival signal REG3a prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease. J Clin Invest. 2018 11 01; 128(11):4970-4979.
    View in: PubMed
    Score: 0.033
  41. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018 06 21; 131(25):2846-2855.
    View in: PubMed
    Score: 0.031
  42. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 03; 24(3):282-291.
    View in: PubMed
    Score: 0.031
  43. Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Mar; 23(3):522-528.
    View in: PubMed
    Score: 0.029
  44. Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. Ann Hematol. 2015 Jun; 94(6):1033-41.
    View in: PubMed
    Score: 0.025
  45. Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation. Blood. 2015 Apr 09; 125(15):2435-44.
    View in: PubMed
    Score: 0.025
  46. Participation in clinical research: perspectives of adult patients and parents of pediatric patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1604-11.
    View in: PubMed
    Score: 0.024
  47. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013 Aug 08; 369(6):529-39.
    View in: PubMed
    Score: 0.023
  48. Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J Clin Invest. 2013 Apr; 123(4):1590-604.
    View in: PubMed
    Score: 0.022
  49. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)? Curr Stem Cell Res Ther. 2012 May; 7(3):229-39.
    View in: PubMed
    Score: 0.021
  50. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood. 2011 Oct 13; 118(15):4258-64.
    View in: PubMed
    Score: 0.020
  51. Graft-versus-host disease. Lancet. 2009 May 02; 373(9674):1550-61.
    View in: PubMed
    Score: 0.017
  52. A biomarker panel for acute graft-versus-host disease. Blood. 2009 Jan 08; 113(2):273-8.
    View in: PubMed
    Score: 0.016
  53. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood. 2008 Aug 15; 112(4):1515-21.
    View in: PubMed
    Score: 0.016
  54. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008 Feb 15; 111(4):2470-5.
    View in: PubMed
    Score: 0.015
  55. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005 Sep; 11(9):680-7.
    View in: PubMed
    Score: 0.013
  56. Critical role of host gammadelta T cells in experimental acute graft-versus-host disease. Blood. 2005 Jul 15; 106(2):749-55.
    View in: PubMed
    Score: 0.013
  57. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease. Blood. 2005 Mar 01; 105(5):2023-7.
    View in: PubMed
    Score: 0.012
  58. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004 Jun 15; 172(12):7393-8.
    View in: PubMed
    Score: 0.012
  59. Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol. 2003 Oct; 31(10):897-902.
    View in: PubMed
    Score: 0.012
  60. Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays. Blood. 2003 Jul 15; 102(2):763-71.
    View in: PubMed
    Score: 0.011
  61. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. J Clin Invest. 2002 May; 109(9):1249-56.
    View in: PubMed
    Score: 0.010
  62. Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8 alpha(+) dendritic cells and reduces experimental acute graft-versus-host disease. Blood. 2002 Mar 01; 99(5):1825-32.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.